XT
ACRV icon

XTX Topco’s Acrivon Therapeutics ACRV Stock Holding History

XTX Topco’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
178,239
+111,357
+166% +$189K ﹤0.01% 2866
2026
Q1 		$93K Buy
66,882
+46,310
+225% +$80.8K ﹤0.01% 3129
2025
Q4 		$49.6K Sell
20,572
-15,383
-43% -$33.4K ﹤0.01% 2837
2025
Q3 		$65.1K Sell
35,955
-70,164
-66% -$98.6K ﹤0.01% 2111
2025
Q2 		$126K Buy
+106,119
New +$146K 0.01% 1831
2024
Q3 		– Sell
-10,493
Closed -$60.9K – 2027
2024
Q2 		$60.9K Buy
+10,493
New +$84.5K 0.01% 1487

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's ACRV Position: Q2 2026 in Review

XTX Topco increased its Acrivon Therapeutics (ACRV) stake by 166% in Q2 2026, buying an estimated $189K and bringing the position to 178,239 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #2866.

XTX Topco first reported a position in ACRV in Q2 2024 and has held it in 6 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

  • XTX Topco held 178,239 shares of Acrivon Therapeutics worth $317K as of Q2 2026.
  • XTX Topco bought 111,357 Acrivon Therapeutics shares in Q2 2026, an estimated $189K.
  • Acrivon Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #2866 holding.
  • XTX Topco first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • 46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.